Invest in Israel Newsletter March 2010 Edition
VC Cafe
APRIL 8, 2010
Through the acquisition of Ratiopharm, which is the second-largest player in the German generics market, Europe’s biggest, Israel’s Teva becomes number one in Europe as its presence in Spain, Italy and France is also boosted. The deal is expected to capture significant synergies for Teva.
Let's personalize your content